Contract drug manufacturer Patheon has named former chief executive of Biogen Idec to be the company’s new CEO. James Mullen’s appointment to lead Patheon (TSX:PTI), based in North Carolina’s Research ...

Great biotech companies tend to dominate at least one indication. In Biogen's case, that indication is multiple sclerosis. Biogen's Avonex and Tysabri are long-standing blockbuster treatments for ...

Biogen Idec has partnered with Google X, Google's business unit for long-term “moonshot” projects, to study outside factors that might contribute to the progression of multiple sclerosis (MS), ...

S&P 500 component Biogen IDEC Inc reported net income above Wall Street’s expectations for the third quarter. Biogen Idec is a global biotechnology company that meets the rising needs of therapeutic ...

) targets: alpha-synuclein, tau and TDP-43. These targets are believed to be relevant for the treatment and prevention of a wide variety of neurodegenerative diseases, including Parkinson's disease, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Cambridge neighbors Biogen Idec Inc. and Alnylam ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Cambridge-based Biogen Idec has begun a collaboration ...

Biotech stocks have taken a punishing nose-dive over the past month as investors step aside following significant gains. However, the current share slide is likely more a result of emotion than any ...

Idec Pharmaceuticals Corp. and Biogen Inc. announced yesterday that they would merge in a $6.8 billion deal that will create a powerhouse in the biotechnology industry, with the new company earning ...

Biogen Idec BIIB today announced the findings from a randomized, multicenter, dose-blinded clinical trial that evaluated the effect of AVONEX dose titration, or gradual dose escalation, on flu-like ...